Titan Pharmaceuticals, Inc., a biopharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. The company’s product development programs focus primarily on important pharmaceutical markets with significant unmet medical needs and commercial potential. Products Probuphine The company develops Probuphine for the treatment of opioid dependence. Probuphine is the first product specifically designed for the long-term treatment of opioid dependence and it utilizes ProNeura, its novel, proprietary, long-term drug delivery technology. Probuphine is designed to maintain a stable, around the clock blood level of the drug buprenorphine, an approved agent for the treatment of opioid dependence. Probuphine is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the daily dosed formulations. In 2012, the company entered into a license agreement with Braeburn Pharmaceuticals Sprl (Braeburn) that grants Braeburn exclusive commercialization rights to Probuphine in the United States and Canada. The clinical and manufacturing development of Probuphine for the treatment of opioid dependence in adult patients is complete. The New Drug Application (NDA) seeking approval for treatment of opioid dependence has been accepted by the United States Food and Drug Administration (FDA) for a Priority Review. Fanapt (iloperidone) Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia being marketed by Novartis in the U.S. The U.S. patent expires in October 2016 (excluding a six-month pediatric extension). Vanda Pharmaceuticals, Inc. (Vanda) owns the development and commercialization rights to the oral and depot formulations of this product for the rest of the world. Patents and Proprietary Rights Four patent applications have been filed which incorporate the use of specific compounds with the continuous delivery technology, including two applications related to Probuphine for the potential treatment of opioid addiction and chronic pain. In June 2010, the United States Patent and Trademark Office (USPTO) issued a patent covering Probuphine for the treatment of opiate addiction. Titan is the assignee of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphine and EVA, a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent would expire in April 2024. Patents have issued in Australia, India, Japan, Mexico and New Zealand. Patents covering certain dopamine agonist implants have been issued or allowed in Europe, Japan, Australia, Canada, South Korea, Mexico, New Zealand, South Africa, and Hong Kong, while prosecution of the patent application continues in the U.S., Israel, India and China. The company holds a license from Sanofi-Aventis under certain issued U.S. patents and certain issued foreign patents relating to iloperidone and its methods of use in the treatment of psychiatric disorders, psychotic disorders and analgesia. The term of the U.S. patent that covers certain aspects of its iloperidone product expires in October 2016, excluding a six month extension possible if an approval of pediatric indication is obtained. The company is the licensee from the University of Iowa Research Foundation (UIRF) of two issued U.S. patents (expiring in 2016) relating to methods of use of gallium compounds to inhibit the growth of P. aeruginosa, and the treatment of infections by pathogens causing chronic pulmonary infection. The company is also the licensee from UIRF of certain rights to patent applications covering the use of gallium complexes in preventing and also treating bacterial biofilm-based infections, for which patents have issued in Australia, Japan, Mexico, New Zealand, and South Africa, and prosecution in the U.S., Canada, Europe, China, Hong Kong, and India continues. History Titan Pharmaceuticals, Inc. was founded in 1992.
titan pharmaceuticals inc
(TTNP:OTCBB - OTCQB)
400 Oyster Point Boulevard
South San Francisco, CA 94080
|Alkermes PLC||$46.77 USD||-0.29|
|Reckitt Benckiser Group PLC||4,957 GBp||+1.00|
|View Industry Companies|
Post a JobJobs
- New York City, NY | Deepa GurnaniPosted: Apr 15
- San Francisco, CA | SmartrecruitersPosted: Apr 09
- Washington, DC | DC BarPosted: Apr 09
- Washington, DC | DC BarPosted: Apr 09
Sponsored Financial Commentaries
To contact TITAN PHARMACEUTICALS INC, please visit www.titanpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.